This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects

1. Diabetic Foot Ulcers - Pipeline Review, H1 2014
This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages,
therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured
news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and
discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built
using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the
latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that
the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by
identifying new targets and MOAs to produce first-in-class and best-in-class products.
Scope
The report provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers The report reviews key pipeline products under drug profile section
which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players
involved in the therapeutics development for Diabetic Foot Ulcers and enlists all their major and minor projects The report summarizes all the dormant and
discontinued pipeline projects A review of the Diabetic Foot Ulcers products under development by companies and universities/research institutes based on
information derived from company and industry-specific sources Pipeline products coverage based on various stages of development ranging from
pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Diabetic
Foot Ulcers pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players
with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the
focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Ulcers Plan mergers
and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Diabetic
Foot Ulcers pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners
with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying discontinued projects and
understanding the factors that drove them from pipeline
table Of Contents
table Of Contents 2
list Of Tables 7
list Of Figures 8
introduction 9
global Markets Direct Report Coverage 9
diabetic Foot Ulcers Overview 10
therapeutics Development 11
pipeline Products For Diabetic Foot Ulcers Overview 11
pipeline Products For Diabetic Foot Ulcers Comparative Analysis 12
diabetic Foot Ulcers Therapeutics Under Development By Companies 13
diabetic Foot Ulcers Therapeutics Under Investigation By Universities/institutes 17
diabetic Foot Ulcers Pipeline Products Glance 18
late Stage Products 18
clinical Stage Products 19
early Stage Products 20
unknown Stage Products 21
diabetic Foot Ulcers Products Under Development By Companies 22
diabetic Foot Ulcers Products Under Investigation By Universities/institutes 24
diabetic Foot Ulcers Companies Involved In Therapeutics Development 25
derma Sciences, Inc. 25
cardium Therapeutics, Inc. 26
glaxosmithkline Plc 27
cardiovascular Biotherapeutics, Inc. 28
stratatech Corporation 29
photopharmica Limited 30
tissue Med Biosciences 31
reliance Life Sciences Pvt. Ltd. 32
nanotherapeutics, Inc. 33
celgene Corporation 34
kaken Pharmaceutical Co., Ltd. 35
cytotools Ag 36
indus Biotech Private Limited 37
Diabetic Foot Ulcers - Pipeline Review, H1 2014

2. phage Pharmaceuticals, Inc. 38
novalead Pharma Pvt. Ltd. 39
firststring Research, Inc. 40
theravasc, Inc. 41
coda Therapeutics, Inc. 42
adocia 43
eyegene, Inc. 44
izun Pharmaceuticals Corporation 45
praxis Pharmaceuticals Inc. 46
oneness Biotech Co., Ltd. 47
aprogen, Inc. 48
pergamum Ab 49
dipexium Pharmaceuticals Llc 50
kasiak Research Pvt. Ltd. 51
diabetic Foot Ulcers Therapeutics Assessment 52
assessment By Monotherapy Products 52
assessment By Target 53
assessment By Mechanism Of Action 56
assessment By Route Of Administration 59
assessment By Molecule Type 61
drug Profiles 64
pexiganan Acetate - Drug Profile 64
product Description 64
mechanism Of Action 64
r&d Progress 64
dermapro Ci-05 - Drug Profile 66
product Description 66
mechanism Of Action 66
r&d Progress 66
trafermin - Drug Profile 68
product Description 68
mechanism Of Action 68
r&d Progress 68
wh-1 - Drug Profile 70
product Description 70
mechanism Of Action 70
r&d Progress 70
dsc-127 - Drug Profile 71
product Description 71
mechanism Of Action 71
r&d Progress 71
cvbt-141b - Drug Profile 73
product Description 73
mechanism Of Action 73
r&d Progress 73
doxycycline - Drug Profile 75
product Description 75
mechanism Of Action 75
r&d Progress 75
gam-501 - Drug Profile 76
product Description 76
mechanism Of Action 76
r&d Progress 76
biochaperone Pdgf-bb - Drug Profile 77
product Description 77
mechanism Of Action 77
r&d Progress 77
coda-001 - Drug Profile 79
product Description 79
mechanism Of Action 79
r&d Progress 79
px-070101 - Drug Profile 81
product Description 81
mechanism Of Action 81
r&d Progress 81
reliderm-dt - Drug Profile 82
product Description 82
mechanism Of Action 82
Diabetic Foot Ulcers - Pipeline Review, H1 2014

3. r&d Progress 82
ppa-904 - Drug Profile 83
product Description 83
mechanism Of Action 83
r&d Progress 83
izn-6d4 - Drug Profile 84
product Description 84
mechanism Of Action 84
r&d Progress 84
granexin - Drug Profile 85
product Description 85
mechanism Of Action 85
r&d Progress 85
cstc-1 - Drug Profile 87
product Description 87
mechanism Of Action 87
r&d Progress 87
esmolol Hydrochloride - Drug Profile 88
product Description 88
mechanism Of Action 88
r&d Progress 88
gentamicin Sulfate - Drug Profile 90
product Description 90
mechanism Of Action 90
r&d Progress 90
gsk-1278863 - Drug Profile 91
product Description 91
mechanism Of Action 91
r&d Progress 91
fibroblast Growth Factor-1 - Drug Profile 93
product Description 93
mechanism Of Action 93
r&d Progress 93
pda-002 - Drug Profile 94
product Description 94
mechanism Of Action 94
r&d Progress 94
tmbp-3 - Drug Profile 95
product Description 95
mechanism Of Action 95
r&d Progress 95
coagulation Factor Xiva (human) - Drug Profile 96
product Description 96
mechanism Of Action 96
r&d Progress 96
rusalatide Acetate - Drug Profile 97
product Description 97
mechanism Of Action 97
r&d Progress 97
indus-820 - Drug Profile 100
product Description 100
mechanism Of Action 100
r&d Progress 100
vld-02 - Drug Profile 101
product Description 101
mechanism Of Action 101
r&d Progress 101
ap-102 - Drug Profile 102
product Description 102
mechanism Of Action 102
r&d Progress 102
drug For Wound Healing - Drug Profile 103
product Description 103
mechanism Of Action 103
r&d Progress 103
stromal Cell Therapy For Diabetic Complications - Drug Profile 104
product Description 104
mechanism Of Action 104
Diabetic Foot Ulcers - Pipeline Review, H1 2014

4. r&d Progress 104
eg-decorin - Drug Profile 105
product Description 105
mechanism Of Action 105
r&d Progress 105
nu-2 - Drug Profile 106
product Description 106
mechanism Of Action 106
r&d Progress 106
mt-003 - Drug Profile 107
product Description 107
mechanism Of Action 107
r&d Progress 107
ca5-hif Gene Therapy For Wound And Ulcers - Drug Profile 108
product Description 108
mechanism Of Action 108
r&d Progress 108
cathelicidin - Drug Profile 109
product Description 109
mechanism Of Action 109
r&d Progress 109
drug For Diabetic Foot Ulcer - Drug Profile 111
product Description 111
mechanism Of Action 111
r&d Progress 111
ll-37 - Drug Profile 112
product Description 112
mechanism Of Action 112
r&d Progress 112
refaheal - Drug Profile 113
product Description 113
mechanism Of Action 113
r&d Progress 113
diabetic Foot Ulcers Recent Pipeline Updates 114
diabetic Foot Ulcers Dormant Projects 125
diabetic Foot Ulcers Discontinued Products 126
diabetic Foot Ulcers Product Development Milestones 127
featured News & Press Releases 127
jan 16, 2014: Derma Sciences Provides Update On Dsc127 Phase 3 Clinical Trials 127
oct 10, 2013: Pergamum Announces Final Data From Phase I/ii Study Of Ll-37 In Patients With Chronic Leg Ulcers 127
sep 10, 2013: Dipexium Provides Locilex Manufacturing Update 128
jul 09, 2013: Dipexium Pharmaceuticals Announces The Issuance Of A New U.s. Patent For Locilex 129
jun 18, 2013: Daewoong Pharma Enters Into Contract With Abdi Ibrahim To Export Easyef To Turkey 129
apr 25, 2013: Derma Sciences Begins Screening Patients In Second Phase Iii Trial With Dsc127 For Healing Diabetic Foot Ulcers 130
mar 18, 2013: Adocia Announces Phase Iii Development Program For Treatment Of Diabetic Foot Ulcer 131
feb 06, 2013: Derma Sciences Initiates Enrollment In Dsc127 Phase Iii Trial For Healing Diabetic Foot Ulcers 131
jan 16, 2013: Dermatools Biotech Launches Phase Iii Clinical Trial With Dermapro For Treatment Of Diabetic Foot Syndrome 133
jan 03, 2013: Dipexium Pharma Receives Special Protocol Assessment From Fda For Phase Iii Trial In Mildly Infected Diabetic Foot Ulcers With Locilex 133
appendix 135
methodology 135
coverage 135
secondary Research 135
primary Research 135
expert Panel Validation 135
contact Us 136
disclaimer 136
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Diabetic Foot Ulcers - Pipeline Review, H1 2014

5. Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Diabetic Foot Ulcers - Pipeline Review, H1 2014